转基因小鼠中LPA的细胞因子基编辑避免了大量的删除
Marcel A Chuecos1, So Hyun Park2, Madhvi M Bhakta3
1Department of Integrative Physiology, Baylor College of Medicine, Houston, TX, 77030. USA; Translational Biology and Molecular Medicine Program, Baylor College of Medicine, Houston, TX, 77030. USA.
概括
细胞酶基编辑 (CBE) 提供了一种新的方法来降低脂蛋白 (Lp) 水平. 这种基因组编辑策略有效地减少了小鼠中的Lp(a),而不会造成显著的有害基因组删除,与CRISPR/Cas9.9不同.
科学领域:
- 心血管遗传学 心血管遗传学
- 基因治疗 基因治疗
- 分子生物学分子生物学
背景情况:
- 脂蛋白 (Lp) 是心血管疾病的基因决定风险因素,影响约20%的人口.
- 目前对升高的Lp (a) 的治疗选择有限,这突显了对新型干预措施的需求.
- 基因组编辑为降低Lp(a) 提供了一个潜在的一次性解决方案,但像CRISPR/Cas9这样的传统方法可能会导致大量的基因组删除.
研究的目的:
- 调查TadA衍生的细胞因子基编辑 (CBE) 的有效性和安全性,以降低脂蛋白 (Lp) 水平.
- 评估通过辅助性腺病毒 (HDAdV) 和腺相关病毒 (AAV) 载体传递的CBE的潜力.
- 在CBE针对LPA基因后评估基因组完整性.
主要方法:
- 利用通过HDAdV和AAV载体传递的TadA衍生的细胞因子基编辑 (CBE),在LPA基因中引入过早停止编码子.
- 使用单分子独特分子标识符 (UMI) 的 SMRT-seq 来量化基因组删除事件.
- 在LPA转基因小鼠模型中比较CBE的基因组影响与CRISPR/Cas9切割.
主要成果:
- 在LPA转基因小鼠中,CBE强大而持久地降低了循环的阿波利波蛋白 (apo) 水平.
- 在针对单个LPA位点时,CBE没有诱导大型基因组删除,并且在多个位点中导致<4%的大型删除.
- CRISPR/Cas9切割LPA主要导致大量的删除,这表明基因组不稳定性风险更高.
结论:
- 在相关的小鼠模型中,TadA衍生CBE是一种有效的策略,用于持续降低apolipoprotein (apo) 的水平.
- 与CRISPR/Cas9.9相比,CBE在很大程度上保持了基因组完整性,证明了有利的安全性.
- 这项研究确立了CBE作为一个有前途的基因组编辑工具,用于管理高脂蛋白 (Lp) 和心血管疾病风险.
相关概念视频
Conservative Site-specific Recombination and Phase Variation
7.0K
Because the DNA segments are cut and reorganized in a direction-specific manner, site-specific recombination has emerged as an efficient genetic engineering technique. Flippase and Cyclization recombinases or Flp and Cre, respectively, are two members of the tyrosine recombinase family derived from bacteriophages, that are used to mediate site-specific DNA insertions, deletions, and targeted expression of proteins in mammalian cell lines.
The recognition sites for Cre recombinase called LoxP...
The recognition sites for Cre recombinase called LoxP...
7.0K
In-vitro Mutagenesis
17.4K
To learn more about the function of a gene, researchers can observe what happens when the gene is inactivated or “knocked out,” by creating genetically engineered knockout animals. Knockout mice have been particularly useful as models for human diseases such as cancer, Parkinson’s disease, and diabetes.
17.4K
RNA Editing
10.0K
RNA editing is a post-transcriptional modification where a precursor mRNA (pre-mRNA) nucleotide sequence is changed by base insertion, deletion, or modification. The extent of RNA editing varies from a few hundred bases, in mitochondrial DNA of trypanosomes, to a just single base, in nuclear genes of mammals. Even a single base change in the pre-mRNA can convert a codon for one amino acid into the codon for another amino acid or a stop codon. This type of re-coding can significantly affect the...
10.0K


